Positive recommendation for Alyftrek in Canada 

Toronto, December 5, 2025 – Cystic Fibrosis Canada welcomes the positive reimbursement recommendation recently issued by Canada Drug Agency for Alyftrek, the latest cystic fibrosis therapy to be approved by Health Canada. 

This recommendation provides a clear signal that public drug plans – including provinces and territories – should move towards covering Alyftrek, enabling Canadians with CF to access this treatment option.  

Alyftrek is a once-daily treatment approved for people aged 6+ with the most common CF gene mutation (F508del) or another responsive mutation. 

For many in Canada’s CF community, Alyftrek could be their first chance at a highly effective CFTR modulator – and for others, it may offer a vital alternative when other treatments have been less effective or not well tolerated, or simply, the freedom of choice when it comes to a CF modulator therapy. 

Cystic Fibrosis Canada urges every public drug plan to move quickly to cover Alyftrek and will continue to advocate for swift access.  

In Québec, drug funding recommendations are made separately by the Institut national d’excellence en santé et en services sociaux (INESSS). Cystic Fibrosis Canada continues to follow this process closely and remains hopeful for a positive outcome for the CF community in that province. 

More information about Alyftrek is available on our blog: https://cysticfibrosis.ca/blog/alyftrek-your-questions-answered